Area of research
Pharmacology · Epidemiology
Research interest
Research interests include Drug-Induced Hepatotoxicity and Protection, Liver Disease Diagnosis and Treatment, Hepatitis C virus research, and Pharmacogenetics and Drug Metabolism.
Protein S-glutathionylation confers cellular resistance to ferroptosis induced by glutathione depletion
Chinese Guideline for the Diagnosis and Management of Drug‐Induced Liver Injury in Primary Care (2024)
Burden of pulmonary arterial hypertension in Asia from 1990 to 2021: Findings from Global Burden of Disease Study 2021
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
Investigation of HO-1 Regulation of Liver Fibrosis Related to Nonalcoholic Fatty Liver Disease Through the SIRT1/TGF-ß/Smad3 Pathway
Intracellular IL-24 ameliorates lipid metabolic disorders in metabolic dysfunction-associated steatohepatitis by restoring the autophagy-lysosome pathway
Pembrolizumab in Patients of Chinese Descent with Microsatellite Instability-high/Mismatch Repair Deficient Advanced Solid Tumors: KEYNOTE-158 Final Analysis
Leukocyte Count as an In‐Hospital Prognostic Indicator in Acute Pulmonary Embolism: Evidence From a Registry Study and Genetic Analyses
4EBP1 phosphorylation mediates TGF-β1-induced hepatic fibrosis and upregulates HIF-1α expression
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158
136P Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
Egr1 confers protection against acetaminophen‑induced hepatotoxicity via transcriptional upregulating of Acaa2
Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations
Hugan tablets for the treatment of RUCAM based drug-induced liver injury: a propensity score matching analysis using a nationwide database
Protecting mitochondria via inhibiting VDAC1 oligomerization alleviates ferroptosis in acetaminophen-induced acute liver injury
Health-related quality of life in Chinese population with non-alcoholic fatty liver disease: a national multicenter survey
Vitamin A and retinoic acid accelerate the attenuation of intestinal adaptability upon feeding induced by high-fat diet in mice
Hugan tablets for the treatment of RUCAM based drug-induced liver injury: a propensity score matching analysis using a nationwide database
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China
Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results
Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial
Sofosbuvir/Velpatasvir for Treatment of Hepatitis C Virus in Asia: An Open-Label, Phase 3 Study
CSH guidelines for the diagnosis and treatment of drug-induced liver injury